Eblasakimab improves multiple disease measures in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded, placebo-controlled, Phase 1 study

eblasakimab (ASLAN004) - ASLAN Pharma, Zenyaku Holdings

Karen Veverka1; Josemund Menezes1; Steven Tien Guan Thng2; Melissa Gooderham3; Eric Simpson4

Apr 24, 2023